DING CHUN R
CIK: 0001250077
DING CHUN R's purchase track record
DING CHUN R has only 2 open-market purchases with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 10/9/2024 | GRAL | $209K | +36.6% | +92.6% | -5.8% |
| 10/1/2024 | GRAL | $815K | +34.7% | +89.4% | -1.3% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| GRAL | ▼ Sell | Open Market | 51,125 | $2.5M | 7/1/2025 | View on chart |
| GRAL | ▼ Sell | Open Market | 260,832 | $12.9M | 7/1/2025 | View on chart |
| GRAL | ▼ Sell | Open Market | 27,843 | $1.4M | 7/1/2025 | View on chart |
| GRAL | ▲ Buy | Open Market | 16,200 | $209K | 10/9/2024 | View on chart |
| GRAL | ▲ Buy | Open Market | 35,000 | $445K | 10/3/2024 | View on chart |
| GRAL | ▼ Sell | Other | 70,000 | $880K | 10/3/2024 | View on chart |
| GRAL | ▲ Buy | Open Market | 20,000 | $267K | 10/2/2024 | View on chart |
| GRAL | ▲ Buy | Open Market | 7,629 | $103K | 10/1/2024 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 11, 2026
Grail hits 12-month high after FDA panel win
Grail stock reached a 12-month high following a favorable FDA panel decision. This event has driven significant price movement, with the stock up 171% over the last six months. While some analysts view the current valuation as high, others see potential for continued growth. The company is also preparing to present new data from major clinical trials at upcoming medical conferences.
Grail hits 12-month high after FDA panel win. Grail stock reached a 12-month high following a favorable FDA panel decision. This event has driven significant price movement, with the stock up 171% over the last six months. While some analysts view the current valuation as high, others see potential for continued growth. The company is also preparing to present new data from major clinical trials at upcoming medical conferences.